CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 23 enrolled
Drug / intervention
Capecitabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01226732
NCT01226732Phase 1Completed
CompareCT.gov

A Phase I Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

SCRI Development Innovations, LLC·interventional·Posted Oct 22, 2010·Updated Mar 8, 2022

In Brief

A Phase 1 clinical trial evaluating Capecitabine and Hsp90 Inhibitor AUY 922 for Metastatic or Unresectable Solid Tumor Malignancy. Completed, enrolled 23 participants across 3 sites.

Detailed Summary

The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors. This combination treatment has potential applicability in tumor types where capecitabine or fluorouracil is a treatment option, including colorectal and breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic or Unresectable Solid Tumor Malignancy
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 22, 2010
Enrollment StartNov 1, 2010
Primary CompletionJul 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 15.7 years ago

Interventions

Capecitabinedrug

Taken orally twice daily on Days 1 through 14 of 21 day cycle.

Hsp90 Inhibitor AUY 922drug

IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle